A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT)
This is a randomized clinical trial (OMIT study) evaluating the efficacy of metastasectomy in patients with oligo-metastatic breast cancer.
Breast Cancer
PROCEDURE: Metastasectomy for the metastatic sites
Overall Survival, Overall survival is calculated from randomization to death from any cause, 3-year
Time To Event (TTE), From date of randomization at baseline to the time of the first event (Disease progression, local recurrence or distant metastasis, contralateral breast cancer, second primary tumor, or death from any cause), whichever came first, assessed up to 60 months, From date of randomization at baseline to the time of the first event, assessed up to 60 months
This is a randomized clinical trial (OMIT study) evaluating the efficacy of metastasectomy in patients with oligo-metastatic breast cancer.